名称:重组人VEGF165
Synonyms:Vascular Endothelial Growth Factor Isoform 165
Species:9
Accession:P15692
GeneID:7422
Source:Escherichia coli.
Molecular Weight:Approximately 38.6 kDa, a disulfide-linked homodimeric protein consisting of two 166 amino acid polypeptide chains with Met at N-terminus.
Quantity:2μg/10μg/1000μg
AA Sequence:MAPMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQENPCGP CSERRKHLFV QDPQTCKCSC KNTDSRCKAR QLELNERTCR CDKPRR
Purity:> 95 % by SDS-PAGE and HPLC analyses.
Biological Activity:Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human umbilical vein endothelial cells(HUVEC) is between 1.0-8.0 ng/ml.
Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation:Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Endotoxin:Less than 1 EU/μg of rHuVEGF165 as determined by LAL method.
Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability & Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reference:1. Leung DW, Cachianes G, Kuang WJ, et al. 1989. Science. 246:1306-9.
2. Byrne AM, Bouchier-Hayes DJ, Harmey JH. 2005. J Cell Mol Med. 9:777-94.
3. Robinson CJ, Stringer SE. 2001. J Cell Sci. 114:853-65.
Background:Vascular Endothelial Growth Factor is a sub-family of growth factors produced by cells, which stimulates vasculogenesis and angiogenesis. VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (a.a.) in length. VEGF production can be induced in cells that are not receiving enough oxygen. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. Recombinant human VEGF165 contains 165 amino acids residues and it is a disulfide-linked homodimer. In addition, it shares 88 % a.a. with corresponding regions of mouse and rat, 96 % with porcine, 95 % with canine, and 93 % with feline, equine and bovine VEGF, respectively